HWAN-SHYR DING: Open Payments
NPI 1982018396 · NORTH PLATTE, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,273 in 112 payments from 11 companies in 2025. Trend: 2023 $570 · 2024 $1,405 · 2025 $2,273
Food & beverage: $2,273
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 21 | $442 |
| E.R. Squibb & Sons, L.L.C. | 19 | $390 |
| ABBVIE INC. | 26 | $386 |
| Alkermes, Inc. | 12 | $308 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $259 |
| Teva Pharmaceuticals USA, Inc. | 13 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $108 |
| Janssen Pharmaceuticals, Inc | 5 | $85 |
| Axsome Therapeutics, Inc. | 4 | $82 |
| Lundbeck LLC | 1 | $18 |
Products named: COBENFY, VRAYLAR, ARISTADA, CAPLYTA, ABILIFY MAINTENA, REXULTI, TRINTELLIX, UZEDY.
Industry payments across NE — which companies pay providers there.
